When Rebecca Skloot first heard the name Henrietta Lacks in a biology class, the scientific story sounded miraculous. Cells taken from a woman who had died decades earlier were still multiplying in laboratories. What stayed with Skloot was a more human question: who was the woman behind them?
That question became ‘The Immortal Life of Henrietta Lacks’, published in 2010 after more than a decade of reporting. On Skloot’s birthday, its enduring power lies not simply in what HeLa cells gave medicine, but in what their story asks medicine to explain.
The Woman Behind HeLa
Henrietta Lacks was 31 when she was treated for cervical cancer at Johns Hopkins Hospital in 1951. Samples from her tumour were given to researchers without her knowledge or consent. Her cells proved extraordinary: they could reproduce continuously in culture, becoming the first human cell line to do so reliably.
HeLa cells supported research involving the polio vaccine, cancer, viruses, gene mapping and in vitro fertilisation. The US National Institutes of Health says more than 110,000 scientific publications cited their use between 1953 and 2018.
Yet the achievement carried a profound imbalance. Lacks died in 1951, while her cells travelled through laboratories around the world. Her family learnt about HeLa years later and struggled to understand how part of their mother could still be alive in laboratories. Skloot’s book restored the person to a story science had largely told through cells.
Consent Was Not Then What It Is Now
It is important not to rewrite 1951 using today’s rules. Federal regulations requiring consent for human-subject research did not yet govern tissue culture as modern readers might expect. That absence of rules is precisely why the case remains so useful to bioethics. The questions have outlived the circumstances. Should patients control how biological material removed from their bodies is used? What happens when tissues become commercially valuable? When genetic information can reveal things about descendants, whose privacy is involved? Skloot herself has argued that such questions about control, profit and tissue research remain unresolved.
Modern regulation has evolved, but the answers remain complicated. The revised US Common Rule created a pathway for “broad consent” covering certain future research involving identifiable biospecimens, yet such consent is not required in every form of secondary research.
A Story That Kept Moving
In 2013, the NIH reached an agreement with the Lacks family, giving them a role in decisions over access to certain HeLa genomic data. A decade later, Lacks’s estate settled a lawsuit against Thermo Fisher Scientific over allegations that the company profited from HeLa cells without consent. The settlement terms remained confidential.
That continuing history explains why Skloot’s book has not become merely a period piece. Its most uncomfortable insight is also its most valuable. Medical progress can be extraordinary while the system producing it still leaves moral debts behind. The real question ‘The Immortal Life of Henrietta Lacks’ gives readers is not whether science should advance, but whether advancement can truly be called progress when the person who made it possible disappears from the story.